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WHIPPLE’S DISEASE
Overview of the Disease
Whipple’s disease (WD) is a rare systemic disease, first de-
scribed in 1907 by the American pathologist George H.
Whipple as an intestinal lipodystrophy. He reported the fatal
illness in a patient with weight loss, chronic cough, fever, and
accumulation of fat in the intestine, mesenteric lymph nodes,
and stool (121a). The hallmark of the disease is the accrual of
periodic-acid Schiff (PAS)-stained foamy macrophages in the
lamina propria. Although G. H. Whipple suggested a bacterial
etiology in his systematic description of the disease in his index
patient (121a), it was not until 1961 that intramacrophagic and
free-living bacilli were observed in patient duodenal biopsies
(16a). The bacteria present a rod-shaped morphology with a
symmetric external membrane that is not found among gram-
positive bacteria, and yet it differs from the external membrane
in gram-negative bacteria because it is devoid of lipopolysac-
charide (LPS) (22a). It surrounds a thin homogeneous layer
and an internal membrane containing polysaccharides, which
are probably responsible for the PAS staining (111). As a result
of phylogenetic studies based on the ssr and rpoB gene se-
quences, the agent, which is now referred to as Tropheryma
whipplei, has been placed among the gram-positive bacteria in
the Actinobacteria clade. Several environmental studies suggest
that T. whipplei is ubiquitous. Indeed, bacterial DNA was de-
tected in 66% of wastewater samples from five different sewage
treatment plants in Germany (72a).
In 1997, culture of T. whipplei was achieved in interleu-
kin-4 (IL-4)-deactivated macrophages; however, it was not
possible to establish stable subcultures (107a). In 2000, our
laboratory successfully cultured T. whipplei from the heart
valve specimen of a patient with endocarditis in a human
fibroblast cell line (HEL) (98). The ability to culture the
organism allowed the generation of antibodies against T.
whipplei (98) and enumeration of the complete genome se-
quence for two strains (7a, 101). Analysis of the genome
sequence, which is approximately 0.9 Mb in length, revealed
deficiencies in the biosynthetic pathways of 16 amino acids.
Addition of the missing amino acids to culture medium
permitted the axenic culture of T. whipplei (102a).
WD is considered to be rare, although no valid estimate of
the incidence is available. The disease was diagnosed in a set of
patients within a familial context (22, 96), which implies an
immunogenetic component in the pathogenesis of WD. Sev-
eral studies have shown a greater prevalence of HLA-B27
antigen in WD patients (26% versus 8% in European and
American populations, respectively) (16, 22), but no causal
association between HLA-B27 presence and infection suscep-
tibility has been demonstrated. The classic symptoms of WD
include weight loss, diarrhea, and chronic arthropathy. How-
ever, it is now known that the disease is often multisystemic,
including possible cardiac and central nervous system involve-
ment, and has clinical manifestations that may be varied and
nonspecific (Table 1). T. whipplei has been detected in 4% of
patients with various gastrointestinal diseases and in 7% of
presumably healthy control subjects (2). T. whipplei DNA has
also been detected in 40% of subgingival and gingival sulcus
samples from healthy individuals (124). The disease is charac-
terized by the persistent bacterial infection of affected tissues,
resulting in recurring relapses and gradual exacerbation. PCR-
based diagnosis of WD, which is accomplished by detection of
the genomic material of T. whipplei, is well defined (30). How-
ever, in practice, some studies raise concerns about the diag-
nostic value of T. whipplei PCR alone. Indeed, peripheral
blood mononuclear cells from four patients with active WD
(confirmed by PAS-positive intestinal biopsies) were negative
by PCR for T. whipplei DNA (74). On the contrary, T. whipplei
DNA has been detected in people without WD (28). Diagnosis
can also be made by examination of biopsy samples using
electron microscopy, which allows visualization of the distinc-
tive trilamellar cell wall of T. whipplei. Serologic tests for the
diagnosis of WD are not yet established, because antibodies
directed against T. whipplei have been measured in subjects
without WD as well as in WD patients (27). Thus, although the
diagnosis is usually made by duodenal biopsy, it can simply be
overlooked in the early stages of WD or in other forms of the
disease when gastrointestinal involvement is not clear.
The Immune Deficiency of WD
Since the initial description of WD, it has been hypothesized
that a preexisting immune deficiency acts as a contributing
factor in the development of the disease. The clinical presen-
tation of the disease does not evoke an opportunistic infection.
The disease does not appear to affect the humoral response,
since total immunoglobulin G (IgG) and IgM levels remain
normal even though IgA levels are higher before treatment
and reach control values thereafter (22, 117). A reduction of B-
and T-cell numbers has been observed with a diminution of the
CD4/CD8 ratio (78). Hence, it is likely that an alteration in
the immune response selectively affects some features of the
response to T. whipplei while not impairing host defenses
against common pathogens. A deficiency of macrophage func-
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tion has been documented in several studies. Although WD
patient macrophages have normal phagocytic activity, they are
unable to degrade bacterial antigens efficiently (13, 22). The
expression of CD11b, the  chain of the phagocytic receptor
CR3 (CD11b/CD18), is reduced in patient macrophages (78).
The production of interleukin-12 (IL-12) by monocytes/mac-
rophages from WD patients has been shown to be defective
(76). IL-12 is mainly produced by monocytes, macrophages,
and dendritic cells and stimulates gamma interferon (IFN-)
production by NK cells and T lymphocytes. IL-12 is pivotal in
the stimulation of Th1 differentiation and IFN--mediated mi-
crobicidal competence of macrophages. Hence, reduced IL-12
production leads to diminished IFN- production by T cells
and defective macrophage activation. The report of a patient
with refractory WD who had an apparent response to IFN-
therapy strengthens this hypothesis (107). In this context, this
immune defect appears to be specific to Tropheryma, since
patients with WD do not suffer from opportunistic infections,
as is commonly reported in IL-12 deficiencies (67). Peripheral
blood mononuclear cells from patients with WD had increased
production of IL-4 in response to stimulation with phytohemag-
glutinin and reduced secretion of IFN- and IL-2 compared to
controls (75). In addition, defective microbicidal activity of
macrophages in WD may be intrinsic, because decreased kill-
ing of Candida tropicalis by monocytes has been observed in
patients in remission (5). Thus, macrophages might be more
susceptible to T. whipplei infection because of decreased clas-
sically activating cytokines and increased alternatively activat-
ing IL-4 (39), indicative of a Th2 immune response.
INTESTINAL MACROPHAGES
T. whipplei organisms are localized within the lamina propria
as determined by in situ hybridization: bacterial RNA was
mainly detected at the top of the villi and below the epithelial
cell basement membrane (32). Dobbins proposed that tissue
infiltration with T. whipplei occurred from the lamina propria
and not from the lumen (21). After bacteria have been deliv-
ered to the subepithelial lamina propria, they encounter intes-
tinal macrophages (68). We will review various aspects of in-
testinal macrophages with special emphasis on desensitization
or anergy that may be essential in the pathophysiology of
intestinal WD.
Tissue Distribution, Phenotype, and
Differentiation of Macrophages
Macrophages derive from myeloid progenitor cells that
first develop into monocytes and enter the blood (69). In the
absence of an inflammatory stimulus, monocytes remain in
the blood flow and are exposed to numerous hormones and
constitutive chemokines involved in homeostasis and in host
defenses that influence their fate. Monocytes then adhere
and migrate through capillary endothelium to peripheral
tissues and lymph nodes, where they differentiate into resi-
dent macrophages (61). In contrast, when inflammatory me-
diators are produced in response to an inciting event, in-
ducible chemokines lead to the recruitment and activation
of macrophages in tissues (53). Intestinal macrophages are
located primarily in the subepithelial region of the lamina
propria and in Peyer’s patches. They constitute 10 to 20% of
mononuclear cells in the intestinal lamina propria (23).
Their local distribution is affected by several factors associ-
ated with the ecology of the intestinal flora (20, 38). Intes-
tinal macrophages are also densely distributed in the colo-
rectal mucosa (89), and their distribution at different sites of
the gastrointestinal tract has been reported in monkeys (54)
and guinea pigs (44), in which intestinal macrophages were
mostly found in the small intestine.
Intestinal macrophages differ markedly from blood mono-
cytes (112–114), the cells from which they are derived (14, 43,
105). They express several markers of myeloid lineage, includ-
ing CD44, CD68, acid phosphatase, nonspecific esterase, and
CD33, a member of the sialoadhesin family of sialic acid-
dependent cell adhesion molecules (Table 2). They do not
express CD14, a major receptor for gram-negative bacteria or
their LPS (112); only colonic macrophages express low levels
of CD14 (43, 103). The lack of CD14 results from down-
regulation of CD14 expression rather than a posttranscrip-
tional control (113). It may account for the low level of muco-
sal inflammation despite an environment rich in “CD14
ligands.” This is reinforced by the nominal expression of re-
ceptors involved in the inflammatory response, such as CR3,
Toll-like receptors 1 to 5 (TLR1 to TLR5), and FcR (CD64,
CD32, and CD16). Intestinal macrophages do not express
CD89 (113), a transmembrane glycoprotein receptor for mono-
meric and polymeric IgA1 and IgA2 (85), which are involved in
IgA transcytosis across the mucosal epithelium (86). The ab-
sence of CD89 prevents IgA-mediated phagocytosis required
for protection against environmental pathogens and IgA-
mediated release of proinflammatory mediators, including re-
active oxygen intermediates, leukotrienes, and prostaglandins
(31, 40).
Spo¨ttl and coworkers attempted to differentiate monocytes
TABLE 1. Epidemiology and clinical symptoms of Whipple’s diseasea
Epidemiology Finding
Reported cases............................................................................ 1,000
Mean age ..................................................................................... 50 yrs
Sex ratio (male/female).............................................................. 8
Familial cases .............................................................................. Few
Major clinical manifestations
Weight loss .............................................................................. 90%
Diarrhea................................................................................... 75%
Arthropathy ............................................................................. 85%
Abdominal pain ...................................................................... 60%
Other symptoms
Arthralgias, arthritis ...............................................................70–90%
Anemia.....................................................................................75–90%
Fever ........................................................................................ 45%
Night sweats
Lymphadenopathy ..................................................................40–50%
Hyperpigmentation.................................................................40–60%
Cardiac manifestations...........................................................35–65%
Pulmonary manifestations .....................................................35–60%
CNS manifestations................................................................20–30%
Ocular manifestations ............................................................ 5–15%
Splenomegaly .......................................................................... 5–10%
a Data were collected from references 22, 26, and 77. CNS, central nervous
system.
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into intestinal-like macrophages in the presence of epithelial
cells (115). This work was based on four observations: (i) in
normal intestinal mucosa, macrophages form a layer in the
subepithelial region of the lamina propria separated by the
basement membrane from the epithelial cells (92); (ii) macro-
phages are concentrated in a band immediately beneath the
luminal intestinal epithelium (93); (iii) the mucosal basement
membrane is perforated with numerous small pores in vivo,
allowing a direct interaction of subepithelial macrophages with
intestinal epithelial cells (118); and (iv) components of the
basement membrane and extracellular matrix are involved in
cell differentiation (49). Using a three-dimensional, organo-
typic model with primary intestinal fibroblasts embedded in a
collagen gel covered with epithelial cells, the authors success-
fully differentiated monocytes into CD14- and CD11b-negative
macrophages within 7 days (115). These macrophages also
lacked CD25, the receptor for IL-2, known to stimulate inflam-
matory functions of monocytes/macrophages. They exhibited
decreased IL-1 transcription in response to LPS, likely due to
the lack of CD14. A recent study describes the use of stromal-
cell-conditioned medium to differentiate monocytes into intes-
tine-like macrophages with a reduced expression of CD14,
CD16, chemokine receptor CCR5, and receptors for chemo-
tactic factors, such as C5a and f-met-leu-phe (114). This con-
ditioned medium also caused a diminution of release of IL-1,
IL-6, IL-10, and tumor necrosis factor (TNF) and an increase
of transforming growth factor- (TGF-) release following
LPS or IFN- stimulation. It is probable that TGF- plays a
role in the diminished release of proinflammatory cytokines.
Note that in vivo, intestinal epithelial cells and lamina propria
mast cells appeared to be the source of mucosal TGF- (114).
Intestinal Macrophages and Immunity
Intestinal macrophages may be considered bipolar cells: they
induce an effective innate response and they restrict inflam-
mation via anergy. First, phagocytic and bactericidal activities
of intestinal macrophages are maintained despite the lack of
cell surface innate immunity receptors (114). Indeed, lamina
propria macrophages exhibited avid phagocytic activity for bo-
vine serum albumin-coated beads (113), Candida albicans
(112), Salmonella enterica serovar Typhimurium, and Esche-
richia coli (114). Intestinal macrophages are strongly bacteri-
cidal: 99% of phagocytosed S. enterica serovar Typhimurium
organisms were killed within the first hour (114). They were
capable of even greater bactericidal activity than monocytes, as
the numbers of live S. enterica serovar Typhimurium or E. coli
organisms recovered from lysed macrophages were an order of
magnitude less than those recovered from blood monocytes
(114). Second, intestinal macrophages contribute to immunity
through the secretion of antimicrobial peptides. Antimicrobial
peptides are mainly expressed by intestinal epithelial cells,
particularly by Paneth cells, but it has recently been shown that
cathelin-related antimicrobial peptide (CRAMP) can be ex-
pressed by murine macrophages. Its production was increased
upon infection with S. enterica serovar Typhimurium, and mac-
rophages lacking CRAMP did not control Salmonella replica-
tion, indicating the role of this peptide in the antimicrobial
arsenal of macrophages (104). Other proteins with antimicro-
bial activity have been identified in the normal human colon
mucosa; they include ubiquicidin, ribosomal proteins L30, L39,
and S19, histones H1.5 and H2B, phospholipase A2, and eo-
sinophil cationic protein (51, 120). Ubiquicidin is expressed by
macrophages, and it exhibits antimicrobial activity against Lis-
teria monocytogenes and S. enterica serovar Typhimurium (47).
Different histone-derived peptides from evolutionarily diverse
species ranging from fish to mammals have antimicrobial prop-
erties against enteric bacteria and can neutralize endotoxin
(12). A recent work revealed Nod2 protein as a critical regu-
lator of bacterial immunity within the intestine (63). Nod2 is
present in macrophages as well as dendritic and Paneth cells
and can be induced in enterocytes. This protein is essential in
the detection of muramyl dipeptide, a conserved structure in
bacterial peptidoglycan, and activation of the adaptive immune
system by acting as an adjuvant receptor for antibody produc-
TABLE 2. Phenotypic characterization of intestinal macrophages and monocytesa
Compound Function Intestinal macrophages Circulating monocytes
CD11b (CR3)  Subunit of complement receptor 3  
CD123 (IL-3R) IL-3 receptor  chain  
CD13 Aminopeptidase N  
CD14 Receptor for LPS-LBP complex  
CD16 (FcRIII) Low-affinity Fc receptor  
CD25 (IL-2R) IL-2 receptor  chain  
CD25  LPS  
CD32 (FcRII) Low-affinity receptor for aggregated Ig  
CD33b Binds sialoconjugates  
CD36 Scavenger receptor  
CD44 Binds hyaluronic acid  
CD64 (FcRI) High-affinity receptor for IgG  
CD68 (macrosialin) Unknown  
CD89 (FcR) IgA receptor  
HLA-DR MHC class II  
Acid phosphatase  
Nonspecific esterase  
TLR1-5 Toll-like receptor  
a Data were collected from references 1 and 112 to 115. LBP, LPS-binding protein.
b A useful marker of intestinal macrophages by flow cytometry.
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tion, either directly or by enhancing the production of -de-
fensins (119, 122).
Despite their role in innate immunity, intestinal macrophages
display profound “inflammatory anergy,” which is critical for the
homeostasis of normal intestinal mucosa. This immunologic
disarmament is likely beneficial for the peripheral nonrespon-
siveness to the abundant antigens to which the mucosa is con-
tinuously exposed (103). It has been shown that bacterial
phagocytosis did not stimulate intestinal macrophages to re-
lease cytokines (114). Down-regulation of surface receptors is
also a strategy to circumvent the inflammatory response. In-
deed, intestinal macrophages did not respond to LPS, probably
because of the lack of CD14. They did not respond to various
stimuli, including Helicobacter pylori urease, heat-killed Staph-
ylococcus aureus, IFN-, or phorbol myristate acetate, as re-
vealed by the undetectable or trace level of IL-1, IL-6, IL-12,
TNF, or IL-8 (114). The low expression of TLR and FcR
might dampen inflammatory signals. Similarly, the low expres-
sion of CR3 may limit the excessive activation of intestinal
macrophages, since CR3 recognizes complement components
produced by intestinal epithelial cells and microbe products via
its lectin site. It is important to note that intestinal macro-
phages did not release IL-10 or TGF-, suggesting that the
anergy does not result from autocrine production of these
anti-inflammatory cytokines.
Anergy of intestinal macrophages may also result from the
uptake of apoptotic material in the lamina propria. Hence,
Nagashima et al. described the presence of “typical intestinal
macrophages” that had round or oval nuclei and relatively abun-
dant cytoplasm containing prominent phagocytosed vesicles or
fragments morphologically resembling so-called apoptotic bodies
in the lamina propria (89). These apoptotic bodies expressed
epithelial cell-associated antigens (CEA, Ber-Ep4, and cytokera-
tin) (89). Macrophage responses to apoptotic cell engulfment
include down-modulation of inflammatory responses (80, 116),
and it has been shown that activated monocytes switch from a
proinflammatory to an anti-inflammatory state following contact
with apoptotic neutrophils (15). Hence, phagocytosis of apoptotic
cells by intestinal macrophages might account for the macrophage
intestinal anergy.
MACROPHAGES: PIVOTAL CELLS IN
WD PATHOPHYSIOLOGY
T. whipplei Specifically Replicates in
Monocyte-Derived Macrophages
We recently showed that monocytes and monocyte-derived
macrophages have differing susceptibilities to T. whipplei (19).
For example, macrophages allowed intracellular bacterial
growth, and bacteria started to replicate at day 6. T. whipplei
intramacrophagic growth was slow, with a doubling time
around 30 h during exponential growth, which is in agreement
with another study on T. whipplei (18 h in HEL cells [98]) as
well as phylogenetically close bacteria such as mycobacteria (20
h [11]). From day 9, the growth rate decreased slowly and
bacteria seemed to enter into stasis after 12 days. T. whipplei
replication was associated with macrophage apoptosis. Apop-
tosis induction was strong (20% of cells became annexin V-
positive after 48 h of incubation) and occurred concomitantly
to IL-1 release. Macrophage apoptosis is likely a key event for
bacterial dissemination of numerous pathogens (Table 3), and
one can suspect that, as for other pathogens, apoptosis induc-
tion is a critical event in the pathophysiology of WD. Shigella
flexneri represents the paradigm of host cellular machinery
subversion to induce apoptosis. Following translocation, S.
flexneri organisms are phagocytosed by macrophages present in
the dome cells of Peyer’s patches. Through their type III se-
cretion system, S. flexneri organisms secrete several proteins,
including IpaB (invasion plasmid antigen B), which is thought
to be essential for invasion of epithelial cells. Furthermore,
IpaB interacts with and activates caspase 1, resulting in apo-
ptosis of the infected cell by activation of other downstream
caspases (126, 127) and release of mature IL-1 by cleavage of
pro-IL-1 (125).
In contrast, we showed that monocytes efficiently killed T.
whipplei within 3 days (19) and did not undergo apoptosis. In
addition, monocytes acquired microbicidal activity which was
associated with thioredoxin, a thiol-containing redox molecule
(see below) (19). It is likely that thioredoxin and glutaredoxin
systems, known to possess anti-poptotic activity for mamma-
lian cells (3), are involved in apoptosis prevention.
IL-16, Critical Cytokine in WD Pathophysiology
We performed microarray experiments to analyze the dif-
ferent behavior of monocytes and macrophages in response to
T. whipplei (19). We showed that IL-12 was repressed in both
monocytes and macrophages following T. whipplei infection.
This result is consistent with other studies reporting decreased
IL-12 production in WD (76) and with the hypothesis that a
specific immune defect is present in WD. However, IL-12
repression does not explain T. whipplei differential survival in
TABLE 3. Bacteria that induce macrophage apoptosis
Bacterial pathogen Reference
Actinobacillus actinomycetemcomitans ........................................... 58
Aeromonas hydrophila ...................................................................... 34
Bacillus anthracis .............................................................................. 95
Bordetella pertussis ............................................................................ 62
Brucella abortus................................................................................. 33
Burkholderia cepacia......................................................................... 52
Chlamydia psittaci ............................................................................. 91
Chlamydia trachomatis ..................................................................... 41
Clostridium difficile ........................................................................... 71
Escherichia coli K-12........................................................................ 66
Francisella tularensis ......................................................................... 65
Helicobacter pylori............................................................................. 37
Leptospira interrogans ....................................................................... 81
Mycobacterium avium ....................................................................... 9
Mycobacterium tuberculosis.............................................................. 59
Parachlamydia acanthamoeba ......................................................... 42
Photobacterium damselae subsp. piscicida ..................................... 25
Salmonella enterica serovar Typhimurium .................................... 46
Salmonella enterica serovar Typhi .................................................. 109
Shigella dysenteriae............................................................................ 102
Shigella flexneri .................................................................................. 127
Tropheryma whipplei ......................................................................... 19
Yersinia enterocolitica ....................................................................... 83
Yersinia pestis .................................................................................... 90
Yersinia pseudotuberculosis .............................................................. 84
Vibrio vulnificans............................................................................... 57
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monocytes and macrophages. In contrast, T. whipplei replica-
tion in macrophages was associated with IL-16 expression.
IL-16 is a proinflammatory cytokine secreted by activated
CD4 and CD8 peripheral blood lymphocytes (8, 121), eo-
sinophils (70), mast cells (106), monocytes (29), and epithelial
cells (7). IL-16 is synthesized in a 631-amino-acid precursor
form (pro-IL-16) (6) and is subsequently cleaved at Ser511 by
activated caspase 3 to generate the mature 123-amino-acid
molecule (123). Mature IL-16 is a chemoattractant for CD4-
expressing immune cells, such as T cells (8), monocytes (17),
dendritic cells (55, 56), and eosinophils (97). IL-16 is also
involved in the production of the proinflammatory cytokines
TNF, IL-1, IL-6, and IL-15 by monocytes (79). The expres-
sion of the IL-16-encoding gene was up-regulated, and IL-16
was secreted by macrophages following T. whipplei infection
(19). In contrast, IL-16 was not secreted by monocytes that
killed T. whipplei. The addition of IL-16 in monocyte cultures
stimulated T. whipplei replication. Conversely, anti-IL-16 anti-
bodies completely abolished T. whipplei replication in macro-
phages. IL-16 seems to stimulate macrophage deactivation,
since costimulation of macrophages with IL-16 and T. whipplei
up-regulated IL-10- and TGF-1-encoding gene expression. It
is likely that the expression of these two cytokines results from
the production of inflammatory cytokines in response to T.
whipplei. Both IL-10 and TGF-1, immunoregulatory cyto-
kines, would be more permissive for bacterial replication. Fi-
nally, serum IL-16 levels are associated with the activity of the
disease: they were higher in patients than in controls, and as
soon as a successful treatment was administrated, IL-16 levels
decreased to control values (19). Thus, WD may be added to
the list of diseases in which IL-16 is involved, such as inflam-
matory bowel diseases (36, 45, 60, 82, 110).
T. whipplei Survival and Redox Context
Different mechanisms may be responsible for the killing of
T. whipplei by monocytes. Transcriptional profiles of T. whip-
plei-infected monocytes were similar to those of LPS or IFN-
classically activated monocytes (19). In humans, T. whipplei is
seen intracellularly (99, 100) or as extracellular metabolically
active bacteria in the intestinal lumen (32). Studies using in-
fection of HeLa cells showed that T. whipplei survives intracel-
lularly by altering the phagosomal environment. Phagosomes
containing bacteria were acidic, and T. whipplei colocalized
with lysosome-associated protein 1 but not with cathepsin D,
indicating that phagolysosome fusion and maturation were in-
complete (35). Interestingly, vacuole acidification was critical
to the survival of the organisms, since agents that increased the
intravacuolar pH decreased bacterial viability (35).
As reported for other intracellular bacteria in which strate-
gies adaptive to host dependence are generally associated with
genome reduction (24), T. whipplei possesses a small genome
(1 Mb). Its analysis reveals striking features: the biosynthetic
pathways for 16 amino acids are missing or impaired, genes
encoding enzymes of the tricarboxylic acid cycle are missing,
and T. whipplei lacks clear homologs for thioredoxin and thio-
redoxin reductase. In addition, the gene encoding glutaredoxin
is missing, and T. whipplei exhibits only a distant homolog to
glutathione reductase (101). Hence, T. whipplei represents the
first example of bacteria without the essential thioredoxin/
glutaredoxin redox pathways. Thioredoxin and glutaredoxin
systems are antioxidant molecules which act as electron donors
for numerous cellular processes. Interestingly, we found that
the killing of T. whipplei by monocytes was associated with
thioredoxin- and glutaredoxin-encoding gene up-regulation
(19). Upon infection, monocytes released active thioredoxin,
whereas both its transcription and release were repressed in
macrophages. Adding exogenous thioredoxin to infected mac-
rophages decreased bacterial replication. We also demon-
strated that thioredoxin is not toxic for T. whipplei, since add-
ing thioredoxin to axenic culture of T. whipplei did not
interfere with bacterial growth (19). Hence, it is likely that
thioredoxin activates monocytes. Indeed, thioredoxin has been
shown to activate NF-B (4) and AP-1 transcription (48), and
this might be the way by which apoptosis is prevented in mono-
cytes. Thioredoxin, and more generally intracellular redox sta-
tus, also affects the Th1-Th2 balance (88), since mice overex-
pressing human thioredoxin exhibit a long-term T-cell
polarization toward Th1 profile (87) depending on the enzy-
matic activity of thioredoxin (10).
Intestinal Macrophages in WD
During WD, the small intestinal mucosa of most patients
is characterized by a loss of microvilli and the infiltration of
large foamy macrophages, which are filled with PAS-positive
material. Ultrastructural studies have shown that T. whipplei
organisms are present in both intracellular and extracellular
locations (111). Recently, we assessed the transcriptional
profile of intestinal macrophages from a patient with refrac-
tory intestinal WD (18). Histological analyses of duodenal
biopsies from this patient showed a massive infiltration of
foamy macrophages in the lamina propria which repre-
sented more than 80% of the cells. These macrophages
contained numerous intracytoplasmic PAS-positive gran-
ules. Only 129 genes were differentially modulated in WD
lesions. Among them, one of the most up-regulated genes
was that encoding CCL18, a chemokine mainly expressed by
monocytes/macrophages and dendritic cells. CCL18 expres-
sion is induced by Th2-associated cytokines, such as IL-4,
IL-13, and IL-10, whereas its expression is repressed by
IFN- (64, 94). We found that IL-10 was strongly induced in
WD lesions and might account for CCL18 expression (18).
CCL18 attracts naı¨ve T cells and is produced by tumor-
associated macrophages (108). Recruitment of naive T cells
in a microenvironment dominated by IL-10, which inhibits
dendritic cell maturation, might result in tolerance and im-
munoregulation. Genes encoding cathepsins, major histo-
compatibility complex (MHC) class II molecules (HLA-DP1
and HLA-DMB), scavenger receptors, CD14, and IL-1 recep-
tor antagonist were also strongly up-regulated in WD lesions.
Up-regulation of cathepsin expression may be associated with
a defective IFN- pathway, since IFN- decreases expression
of cathepsin B in macrophages (50). These results are in ac-
cordance with the successful treatment of a patient with re-
fractory intestinal WD with IFN- therapy (107). Interestingly,
all these up-regulated genes have been associated with the
M2/alternatively activated phenotype of macrophages (39, 73).
The M2/alternatively activated transcriptional signature of in-
testinal macrophages in WD lesions is distinct from that of
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circulating monocytes and derived macrophages, in which
IL-16 seems to be critical (see above) (19). We propose the
following model to explain this difference (Fig. 1). Once they
have reached the lamina propria by an unknown mechanism,
T. whipplei organisms are engulfed by resident intestinal mac-
rophages, which then shift toward the M2/alternatively acti-
vated phenotype. They produce high levels of CCL18, IL-10,
and TYRO binding protein (DAP12) (18), which may attract
other macrophages and naive T cells and orient the local im-
mune response toward a Th2 response. Newly recruited mac-
rophages engulf bacteria and produce IL-16 and IL-1 and
undergo apoptosis. T. whipplei infection could then spread
gradually. In the intestinal mucosa, IL-16 could promote im-
mature dendritic cell maturation into tolerogenic dendritic
cells that orchestrate tolerance of T. whipplei. Apoptosis of
infected cells could also play a role by inducing anti-inflamma-
tory cytokine release by macrophages following phagocytosis.
Migration of infected dendritic cells or lymphocytes could
propagate infection in other lymphoid organs.
CONCLUDING REMARKS
It has recently been shown that there is an association be-
tween immunosuppressive therapy and the onset of diarrhea in
WD, supporting the concept that immunologic factors play a
role in disease pathogenesis (72). Macrophages, particularly
those of the intestinal mucosa, seem to be of central impor-
tance in the development of the disease. The close proximity of
bacteria and bacterial products, the local expression of numer-
ous cytokines, and the presence of endogenous mucosal factors
probably perpetuate and amplify T. whipplei infection in gas-
trointestinal tract mucosa. Exploring the underlying immune
defects is required to explain why this ubiquitous microorgan-
ism causes disease only in certain individuals.
ACKNOWLEDGMENTS
This work was supported by a fellowship grant from “Fondation
pour la Recherche Me´dicale” and through the 5th “Programme Cadre
de Recherche Technologique” of the European Union (grant no.
QRLT-2001-01049).
REFERENCES
1. Allison, M. C., S. Cornwall, L. W. Poulter, A. P. Dhillon, and R. E. Pounder.
1988. Macrophage heterogeneity in normal colonic mucosa and in inflam-
matory bowel disease. Gut 29:1531–1538.
2. Amsler, L., P. Bauernfeind, C. Nigg, R. C. Maibach, R. Steffen, and M.
Altwegg. 2003. Prevalence of Tropheryma whipplei DNA in patients with
various gastrointestinal diseases and in healthy controls. Infection 31:81–85.
3. Arner, E. S., and A. Holmgren. 2000. Physiological functions of thioredoxin
and thioredoxin reductase. Eur. J. Biochem. 267:6102–6109.
4. Baeuerle, P. A., and T. Henkel. 1994. Function and activation of NF-kappa
B in the immune system. Annu. Rev. Immunol. 12:141–179.
5. Bai, J. C., L. Sen, R. Diez, S. Niveloni, E. C. Maurino, M. E. Estevez, and
L. A. Boerr. 1996. Impaired monocyte function in patients successfully
treated for Whipple’s disease. Acta Gastroenterol. Latinoam. 26:85–89.
6. Baier, M., N. Bannert, A. Werner, K. Lang, and R. Kurth. 1997. Molecular
cloning, sequence, expression, and processing of the interleukin 16 precur-
sor. Proc. Natl. Acad. Sci. USA 94:5273–5277.
7. Bellini, A., H. Yoshimura, E. Vittori, M. Marini, and S. Mattoli. 1993.
Bronchial epithelial cells of patients with asthma release chemoattractant
factors for T lymphocytes. J. Allergy Clin. Immunol. 92:412–424.
7a.Bentley, S. D., M. Maiwald, L. D. Murphy, M. J. Pallen, C. A. Yeats, L. G.
Dover, H. T. Norbertczak, G. S. Besra, M. A. Quail, D. E. Harris, A. von
Herbay, A. Goble, S. Rutter, R. Squares, S. Squares, B. G. Barrell, J.
Parkhill, and D. A. Relman. 2003. Sequencing and analysis of the genome
of the Whipple’s disease bacterium Tropheryma whipplei. Lancet 361:637–
644.
8. Berman, J. S., W. W. Cruikshank, D. M. Center, A. C. Theodore, and D. J.
Beer. 1985. Chemoattractant lymphokines specific for the helper/inducer
T-lymphocyte subset. Cell Immunol. 95:105–112.
9. Bermudez, L. E., A. Parker, and M. Petrofsky. 1999. Apoptosis of Myco-
bacterium avium-infected macrophages is mediated by both tumour necro-
sis factor (TNF) and Fas, and involves the activation of caspases. Clin. Exp.
Immunol. 116:94–99.
FIG. 1. Model illustrating the pathophysiology of Whipple’s disease. DC, dendritic cells.
VOL. 13, 2006 MINIREVIEWS 175
10. Bertini, R., O. M. Howard, H. F. Dong, J. J. Oppenheim, C. Bizzarri, R.
Sergi, G. Caselli, S. Pagliei, B. Romines, J. A. Wilshire, M. Mengozzi, H.
Nakamura, J. Yodoi, K. Pekkari, R. Gurunath, A. Holmgren, L. A.
Herzenberg, and P. Ghezzi. 1999. Thioredoxin, a redox enzyme released in
infection and inflammation, is a unique chemoattractant for neutrophils,
monocytes, and T cells. J. Exp. Med. 189:1783–1789.
11. Beste, D. J. V., J. Peters, T. Hooper, C. Avignone-Rossa, M. E. Bushell, and
J. McFadden. 2005. Compiling a molecular inventory for Mycobacterium
bovis BCG at two growth rates: evidence for growth rate-mediated regula-
tion of ribosome biosynthesis and lipid metabolism. J. Bacteriol. 187:1677–
1684.
12. Birkemo, G. A., T. Luders, O. Andersen, I. F. Nes, and J. Nissen-Meyer.
2003. Hipposin, a histone-derived antimicrobial peptide in Atlantic halibut
(Hippoglossus hippoglossus L.). Biochim. Biophys. Acta 1646:207–215.
13. Bjerknes, R., S. Odegaard, R. Bjerkvig, B. Borkje, and O. D. Laerum. 1988.
Whipple’s disease. Demonstration of a persisting monocyte and macro-
phage dysfunction. Scand. J. Gastroenterol. 23:611–619.
14. Burgio, V. L., S. Fais, M. Boirivant, A. Perrone, and F. Pallone. 1995.
Peripheral monocyte and naive T-cell recruitment and activation in Crohn’s
disease. Gastroenterology 109:1029–1038.
15. Byrne, A., and D. J. Reen. 2002. Lipopolysaccharide induces rapid produc-
tion of IL-10 by monocytes in the presence of apoptotic neutrophils. J. Im-
munol. 168:1968–1977.
16. Canoso, J. J., M. Saini, and J. A. Hermos. 1978. Whipple’s disease and
ankylosing spondylitis simultaneous occurrence in HLA-B27 positive male.
J. Rheumatol. 5:79–84.
16a.Chears, W. C., and C. T. Ashworth. 1961. Electron microscopic study of the
intestinal mucosa in Whipple’s disease. Demonstration of encapsulated
bacilliform bodies in the lesion. Gastroenterology 41:129–138.
17. Cruikshank, W. W., J. S. Berman, A. C. Theodore, J. Bernardo, and D. M.
Center. 1987. Lymphokine activation of T4 T lymphocytes and monocytes.
J. Immunol. 138:3817–3823.
18. Desnues, B., H. Lepidi, D. Raoult, and J. L. Mege. 2005. Whipple’s disease:
intestinal infiltrating cells exhibit transcriptional pattern of M2/alternatively
activated macrophages. J. Infect. Dis. 192:1642–1646.
19. Desnues, B., D. Raoult, and J. L. Mege. 2005. Interleukin-16 is critical for
Tropheryma whipplei replication in Whipple’s disease. J. Immunol. 175:
4575–4582.
20. Dickman, M. D., A. R. Chappelka, and R. W. Schaedler. 1976. The micro-
bial ecology of the upper small bowel. Am. J. Gastroenterol. 65:57–62.
21. Dobbins, W. O., III. 1995. The diagnosis of Whipple’s disease. N. Engl.
J. Med. 332:390–392.
22. Dobbins, W. O., III. 1987. Whipple’s disease. Charles C. Thomas, Spring-
field, Ill.
22a.Dobbins, W. O., III, and H. Kawanishi 1981. Bacillary characteristics in
Whipple’s disease: an electron microscopic study. Gastroenterology 80:
1468–1475.
23. Donnellan, W. L. 1965. The structure of the colonic mucosa. The epithe-
lium and subepithelial reticulohistiocytic complex. Gastroenterology 49:
496–514.
24. Doolittle, R. F. 2002. Biodiversity: microbial genomes multiply. Nature
416:697–700.
25. do Vale, A., F. Marques, and M. T. Silva. 2003. Apoptosis of sea bass
(Dicentrarchus labrax L.) neutrophils and macrophages induced by experi-
mental infection with Photobacterium damselae subsp. piscicida. Fish Shell-
fish Immunol. 15:129–144.
26. Dutly, F., and M. Altwegg. 2001. Whipple’s disease and “Tropheryma whip-
pelii.” Clin. Microbiol. Rev. 14:561–583.
27. Dutly, F., H. P. Hinrikson, T. Seidel, S. Morgenegg, M. Altwegg, and P.
Bauerfeind. 2000. Tropheryma whippelii DNA in saliva of patients without
Whipple’s disease. Infection 28:219–222.
28. Ehrbar, H. U., P. Bauerfeind, F. Dutly, H. R. Koelz, and M. Altwegg. 1999.
PCR-positive tests for Tropheryma whipplei in patients without Whipple’s
disease. Lancet 353:2214.
29. Elssner, A., A. I. Doseff, M. Duncan, M. Kotur, and M. D. Wewers. 2004.
IL-16 is constitutively present in peripheral blood monocytes and sponta-
neously released during apoptosis. J. Immunol. 172:7721–7725.
30. Fenollar, F., P. E. Fournier, C. Robert, and D. Raoult. 2004. Use of genome
selected repeated sequences increases the sensitivity of PCR detection of
Tropheryma whipplei. J. Clin. Microbiol. 42:401–403.
31. Ferreri, N. R., W. C. Howland, and H. L. Spiegelberg. 1986. Release of
leukotrienes C4 and B4 and prostaglandin E2 from human monocytes
stimulated with aggregated IgG, IgA, and IgE. J. Immunol. 136:4188–4193.
32. Fredricks, D. N., and D. A. Relman. 2001. Localization of Tropheryma
whippelii rRNA in tissues from patients with Whipple’s disease. J. Infect.
Dis. 183:1229–1237.
33. Galdiero, E., C. Romano Carratelli, M. Vitiello, I. Nuzzo, E. Del Vecchio, C.
Bentivoglio, G. Perillo, and F. Galdiero. 2000. HSP and apoptosis in leu-
kocytes from infected or vaccinated animals by Brucella abortus. New Mi-
crobiol. 23:271.
34. Galindo, C. L., J. Sha, D. A. Ribardo, A. A. Fadl, L. Pillai, and A. K.
Chopra. 2003. Identification of Aeromonas hydrophila cytotoxic enterotoxin-
induced genes in macrophages using microarrays. J. Biol. Chem.
278:40198–40212.
35. Ghigo, E., C. Capo, M. Aurouze, C. H. Tung, J. P. Gorvel, D. Raoult, and
J. L. Mege. 2002. Survival of Tropheryma whipplei, the agent of Whipple’s
disease, requires phagosome acidification. Infect. Immun. 70:1501–1506.
36. Glas, J., H. P. Torok, H. Unterhuber, M. Radlmayr, and C. Folwaczny.
2003. The -295T-to-C promoter polymorphism of the IL-16 gene is associ-
ated with Crohn’s disease. Clin. Immunol. 106:197–200.
37. Gobert, A. P., Y. Cheng, J. Y. Wang, J. L. Boucher, R. K. Iyer, S. D.
Cederbaum, R. A. Casero, Jr., J. C. Newton, and K. T. Wilson. 2002.
Helicobacter pylori induces macrophage apoptosis by activation of arginase
II. J. Immunol. 168:4692–4700.
38. Gorbach, S. L., L. Nahas, P. I. Lerner, and L. Weinstein. 1967. Studies of
intestinal microflora. I. Effects of diet, age, and periodic sampling on num-
bers of fecal microorganisms in man. Gastroenterology 53:845–855.
39. Gordon, S. 2003. Alternative activation of macrophages. Nat. Rev. Immu-
nol. 3:23–35.
40. Gorter, A., P. S. Hiemstra, P. C. Leijh, M. E. van der Sluys, M. T. van den
Barselaar, L. A. van Es, and M. R. Daha. 1987. IgA- and secretory IgA-
opsonized S. aureus induce a respiratory burst and phagocytosis by poly-
morphonuclear leucocytes. Immunology 61:303–309.
41. Goth, S. R., and R. S. Stephens. 2001. Rapid, transient phosphatidylserine
externalization induced in host cells by infection with Chlamydia spp. Infect.
Immun. 69:1109–1119.
42. Greub, G., J. L. Mege, and D. Raoult. 2003. Parachlamydia acanthamoebae
enters and multiplies within human macrophages and induces their apop-
tosis. Infect. Immun. 71:5979–5985.
43. Grimm, M. C., P. Pavli, E. Van de Pol, and W. F. Doe. 1995. Evidence for
a CD14 population of monocytes in inflammatory bowel disease mucosa-
implications for pathogenesis. Clin. Exp. Immunol. 100:291–297.
44. Han, H., T. Iwanaga, Y. Uchiyama, and T. Fujita. 1993. Aggregation of
macrophages in the tip of intestinal villi in guinea pigs: their possible role
in the phagocytosis of effete epithelial cells. Cell Tissue Res. 271:407–416.
45. He, S. H. 2004. Key role of mast cells and their major secretory products in
inflammatory bowel disease. World J. Gastroenterol. 10:309–318.
46. Hersh, D., D. M. Monack, M. R. Smith, N. Ghori, S. Falkow, and A.
Zychlinsky. 1999. The Salmonella invasin SipB induces macrophage apop-
tosis by binding to caspase-1. Proc. Natl. Acad. Sci. USA 96:2396–2401.
47. Hiemstra, P. S., M. T. van den Barselaar, M. Roest, P. H. Nibbering, and
R. van Furth. 1999. Ubiquicidin, a novel murine microbicidal protein
present in the cytosolic fraction of macrophages. J. Leukoc. Biol. 66:423–
428.
48. Hirota, K., M. Matsui, S. Iwata, A. Nishiyama, K. Mori, and J. Yodoi. 1997.
AP-1 transcriptional activity is regulated by a direct association between
thioredoxin and Ref-1. Proc. Natl. Acad. Sci. USA 94:3633–3638.
49. Hohn, H. P., R. Grummer, S. Bosserhoff, S. Graf-Lingnau, B. Reuss, C.
Backer, and H. W. Denker. 1996. The role of matrix contact and of cell-cell
interactions in choriocarcinoma cell differentiation. Eur. J. Cell Biol. 69:
76–85.
50. Honey, K., and A. Y. Rudensky. 2003. Lysosomal cysteine proteases regu-
late antigen presentation. Nat. Rev. Immunol. 3:472–482.
51. Howell, S. J., D. Wilk, S. P. Yadav, and C. L. Bevins. 2003. Antimicrobial
polypeptides of the human colonic epithelium. Peptides 24:1763–1770.
52. Hutchison, M. L., I. R. Poxton, and J. R. Govan. 1998. Burkholderia cepacia
produces a hemolysin that is capable of inducing apoptosis and degranu-
lation of mammalian phagocytes. Infect. Immun. 66:2033–2039.
53. Imhof, B. A., and M. Aurrand-Lions. 2004. Adhesion mechanisms regulat-
ing the migration of monocytes. Nat. Rev. Immunol. 4:432–444.
54. Iwanaga, T., H. Han, and T. Fujita. 1992. Macrophages possibly involved in
the disposal of apoptotic epithelial cells in the monkey small and large
intestine. Acta. Med. Biol. 40:105–113.
55. Kaser, A., S. Dunzendorfer, F. A. Offner, O. Ludwiczek, B. Enrich, R. O.
Koch, W. W. Cruikshank, C. J. Wiedermann, and H. Tilg. 2000. B lympho-
cyte-derived IL-16 attracts dendritic cells and Th cells. J. Immunol. 165:
2474–2480.
56. Kaser, A., S. Dunzendorfer, F. A. Offner, T. Ryan, A. Schwabegger, W. W.
Cruikshank, C. J. Wiedermann, and H. Tilg. 1999. A role for IL-16 in the
cross-talk between dendritic cells and T cells. J. Immunol. 163:3232–3238.
57. Kashimoto, T., S. Ueno, M. Hanajima, H. Hayashi, Y. Akeda, S. Miyoshi,
T. Hongo, T. Honda, and N. Susa. 2003. Vibrio vulnificus induces macro-
phage apoptosis in vitro and in vivo. Infect. Immun. 71:533–535.
58. Kato, S., M. Muro, S. Akifusa, N. Hanada, I. Semba, T. Fujii, Y. Kowashi,
and T. Nishihara. 1995. Evidence for apoptosis of murine macrophages by
Actinobacillus actinomycetemcomitans infection. Infect. Immun. 63:3914–
3919.
59. Keane, J., M. K. Balcewicz-Sablinska, H. G. Remold, G. L. Chupp, B. B.
Meek, M. J. Fenton, and H. Kornfeld. 1997. Infection by Mycobacterium
tuberculosis promotes human alveolar macrophage apoptosis. Infect. Im-
mun. 65:298–304.
60. Keates, A. C., I. Castagliuolo, W. W. Cruickshank, B. Qiu, K. O. Arseneau,
W. Brazer, and C. P. Kelly. 2000. Interleukin 16 is up-regulated in Crohn’s
176 MINIREVIEWS CLIN. VACCINE IMMUNOL.
disease and participates in TNBS colitis in mice. Gastroenterology 119:972–
982.
61. Kennedy, D. W., and J. L. Abkowitz. 1997. Kinetics of central nervous
system microglial and macrophage engraftment: analysis using a transgenic
bone marrow transplantation model. Blood 90:986–993.
62. Khelef, N., A. Zychlinsky, and N. Guiso. 1993. Bordetella pertussis induces
apoptosis in macrophages: role of adenylate cyclase-hemolysin. Infect. Im-
mun. 61:4064–4071.
63. Kobayashi, K. S., M. Chamaillard, Y. Ogura, O. Henegariu, N. Inohara, G.
Nunez, and R. A. Flavell. 2005. Nod2-dependent regulation of innate and
adaptive immunity in the intestinal tract. Science 307:731–734.
64. Kodelja, V., C. Muller, O. Politz, N. Hakij, C. E. Orfanos, and S. Goerdt.
1998. Alternative macrophage activation-associated CC-chemokine-1, a
novel structural homologue of macrophage inflammatory protein-1  with
a Th2-associated expression pattern. J. Immunol. 160:1411–1418.
65. Lai, X. H., and A. Sjostedt. 2003. Delineation of the molecular mechanisms
of Francisella tularensis-induced apoptosis in murine macrophages. Infect.
Immun. 71:4642–4646.
66. Lai, X. H., J. G. Xu, S. Melgar, and B. E. Uhlin. 1999. An apoptotic
response by J774 macrophage cells is common upon infection with diar-
rheagenic Escherichia coli. FEMS Microbiol. Lett. 172:29–34.
67. Lammas, D. A., E. De Heer, J. D. Edgar, V. Novelli, A. Ben-Smith, R.
Baretto, P. Drysdale, J. Binch, C. MacLennan, D. S. Kumararatne, S.
Panchalingam, T. H. Ottenhoff, J. L. Casanova, and J. F. Emile. 2002.
Heterogeneity in the granulomatous response to mycobacterial infection in
patients with defined genetic mutations in the interleukin 12-dependent
interferon-gamma production pathway. Int. J. Exp. Pathol. 83:1–20.
68. Lee, S. H., P. M. Starkey, and S. Gordon. 1985. Quantitative analysis of
total macrophage content in adult mouse tissues. Immunochemical studies
with monoclonal antibody F4/80. J. Exp. Med. 161:475–489.
69. Lewis, C. E., and J. O. McGee. 1992. The macrophage. Oxford University
Press, Oxford, United Kingdom.
70. Lim, K. G., H. C. Wan, M. Resnick, D. T. Wong, W. W. Cruikshank, H.
Kornfeld, D. M. Center, and P. F. Weller. 1995. Human eosinophils release
the lymphocyte and eosinophil active cytokines, RANTES and lymphocyte
chemoattractant factor. Int. Arch. Allergy Immunol. 107:342.
71. Mahida, Y. R., A. Galvin, S. Makh, S. Hyde, L. Sanfilippo, S. P. Borriello,
and H. F. Sewell. 1998. Effect of Clostridium difficile toxin A on human
colonic lamina propria cells: early loss of macrophages followed by T-cell
apoptosis. Infect. Immun. 66:5462–5469.
72. Mahnel, R., A. Kalt, S. Ring, A. Stallmach, W. Strober, and T. Marth. 2005.
Immunosuppressive therapy in Whipple’s disease patients is associated with
the appearance of gastrointestinal manifestations. Am. J. Gastroenterol.
100:1167–1173.
72a.Maiwald, M., F. Schuhmacher, H. J. Ditton, and A. von Herbay. 1998.
Environmental occurrence of the Whipple’s disease bacterium (Tropheryma
whippelii). Appl. Environ. Microbiol. 64:760–762.
73. Mantovani, A., A. Sica, S. Sozzani, P. Allavena, A. Vecchi, and M. Locati.
2004. The chemokine system in diverse forms of macrophage activation and
polarization. Trends Immunol. 25:677–686.
74. Marth, T., D. Fredericks, W. Strober, and D. A. Relman. 1996. Limited role
for PCR-based diagnosis of Whipple’s disease from peripheral blood mono-
nuclear cells. Lancet 348:66–67.
75. Marth, T., N. Kleen, A. Stallmach, S. Ring, S. Aziz, C. Schmidt, W. Strober,
M. Zeitz, and T. Schneider. 2002. Dysregulated peripheral and mucosal
Th1/Th2 response in Whipple’s disease. Gastroenterology 123:1468–1477.
76. Marth, T., M. Neurath, B. A. Cuccherini, and W. Strober. 1997. Defects of
monocyte interleukin 12 production and humoral immunity in Whipple’s
disease. Gastroenterology 113:442–448.
77. Marth, T., and D. Raoult. 2003. Whipple’s disease. Lancet 361:239–246.
78. Marth, T., M. Roux, A. von Herbay, S. C. Meuer, and G. E. Feurle. 1994.
Persistent reduction of complement receptor 3 alpha-chain expressing
mononuclear blood cells and transient inhibitory serum factors in Whip-
ple’s disease. Clin. Immunol. Immunopathol. 72:217–226.
79. Mathy, N. L., W. Scheuer, M. Lanzendorfer, K. Honold, D. Ambrosius, S.
Norley, and R. Kurth. 2000. Interleukin-16 stimulates the expression and
production of pro-inflammatory cytokines by human monocytes. Immunol-
ogy 100:63–69.
80. Meagher, L. C., J. S. Savill, A. Baker, R. W. Fuller, and C. Haslett. 1992.
Phagocytosis of apoptotic neutrophils does not induce macrophage release
of thromboxane B2. J. Leukoc. Biol. 52:269–273.
81. Merien, F., G. Baranton, and P. Perolat. 1997. Invasion of Vero cells and
induction of apoptosis in macrophages by pathogenic Leptospira interrogans
are correlated with virulence. Infect. Immun. 65:729–738.
82. Middel, P., K. Reich, F. Polzien, V. Blaschke, B. Hemmerlein, J. Herms, M.
Korabiowska, and H. J. Radzun. 2001. Interleukin 16 expression and phe-
notype of interleukin 16 producing cells in Crohn’s disease. Gut 49:795–803.
83. Mills, S. D., A. Boland, M. P. Sory, P. van der Smissen, C. Kerbourch, B. B.
Finlay, and G. R. Cornelis. 1997. Yersinia enterocolitica induces apoptosis in
macrophages by a process requiring functional type III secretion and trans-
location mechanisms and involving YopP, presumably acting as an effector
protein. Proc. Natl. Acad. Sci. USA 94:12638–12643.
84. Monack, D. M., J. Mecsas, N. Ghori, and S. Falkow. 1997. Yersinia signals
macrophages to undergo apoptosis and YopJ is necessary for this cell death.
Proc. Natl. Acad. Sci. USA 94:10385–10390.
85. Morton, H. C., M. van Egmond, and J. G. van de Winkel. 1996. Structure
and function of human IgA Fc receptors (Fc  R). Crit. Rev. Immunol.
16:423–440.
86. Mostov, K., and C. S. Kaetzel. 1999. Immunoglobulin transport and the
polymeric immunoglobulin receptor, p. 181. In P. L. Ogra, J. Mestecky,
M. E. Lamm, W. Strober, J. Bienenstock, and J. R. McGhee (ed.), Mucosal
immunology. Academic Press, San Diego, Calif.
87. Murata, Y., M. Amao, J. Yoneda, and J. Hamuro. 2002. Intracellular thiol
redox status of macrophages directs the Th1 skewing in thioredoxin trans-
genic mice during aging. Mol. Immunol. 38:747–757.
88. Murata, Y., T. Shimamura, and J. Hamuro. 2002. The polarization of
Th1/Th2 balance is dependent on the intracellular thiol redox status of
macrophages due to the distinctive cytokine production. Int. Immunol.
14:201–212.
89. Nagashima, R., K. Maeda, Y. Imai, and T. Takahashi. 1996. Lamina
propria macrophages in the human gastrointestinal mucosa: their distribu-
tion, immunohistological phenotype, and function. J. Histochem. Cyto-
chem. 44:721–731.
90. Ng, L. C., O. Forslund, S. Koh, K. Kuoppa, and A. Sjostedt. 2003. The
response of murine macrophages to infection with Yersinia pestis as re-
vealed by DNA microarray analysis. Adv. Exp. Med. Biol. 529:155–160.
91. Ojcius, D. M., P. Souque, J. L. Perfettini, and A. Dautry-Varsat. 1998.
Apoptosis of epithelial cells and macrophages due to infection with the
obligate intracellular pathogen Chlamydia psittaci. J. Immunol. 161:4220–
4226.
92. Pavli, P., and W. F. Doe. 1992. Intestinal macrophages, p. 177–188. In R. P.
MacDermott and W. F. Stenson (ed.), Inflammatory bowel disease.
Elsevier, New York, N.Y.
93. Pavli, P., L. Maxwell, E. Van de Pol, and F. Doe. 1996. Distribution of
human colonic dendritic cells and macrophages. Clin. Exp. Immunol. 104:
124–132.
94. Politz, O., V. Kodelja, P. Guillot, C. E. Orfanos, and S. Goerdt. 2000.
Pseudoexons and regulatory elements in the genomic sequence of the
beta-chemokine, alternative macrophage activation-associated CC-chemo-
kine (AMAC)-1. Cytokine 12:120–126.
95. Popov, S. G., R. Villasmil, J. Bernardi, E. Grene, J. Cardwell, A. Wu, D.
Alibek, C. Bailey, and K. Alibek. 2002. Lethal toxin of Bacillus anthracis
causes apoptosis of macrophages. Biochem. Biophys. Res. Commun. 293:
349–355.
96. Puite, R. H., and H. Tesluk. 1955. Whipple’s disease. Am. J. Med. 19:383–
400.
97. Rand, T. H., W. W. Cruikshank, D. M. Center, and P. F. Weller. 1991.
CD4-mediated stimulation of human eosinophils: lymphocyte chemoattrac-
tant factor and other CD4-binding ligands elicit eosinophil migration. J.
Exp. Med. 173:1521–1528.
98. Raoult, D., M. L. Birg, B. La Scola, P. E. Fournier, M. Enea, H. Lepidi, V.
Roux, J. C. Piette, F. Vandenesch, D. Vital-Durand, and T. J. Marrie. 2000.
Cultivation of the bacillus of Whipple’s disease. N. Engl. J. Med. 342:620–
625.
99. Raoult, D., B. La Scola, P. Lecocq, H. Lepidi, and P. E. Fournier. 2001.
Culture and immunological detection of Tropheryma whippelii from the
duodenum of a patient with Whipple disease. JAMA 285:1039–1043.
100. Raoult, D., H. Lepidi, and J. R. Harle. 2001. Tropheryma whipplei circulat-
ing in blood monocytes. N. Engl. J. Med. 345:548.
101. Raoult, D., H. Ogata, S. Audic, C. Robert, K. Suhre, M. Drancourt, and
J. M. Claverie. 2003. Tropheryma whipplei twist: a human pathogenic acti-
nobacteria with a reduced genome. Genome Res. 13:1800–1809.
102. Raqib, R., C. Ekberg, P. Sharkar, P. K. Bardhan, A. Zychlinsky, P. J.
Sansonetti, and J. Andersson. 2002. Apoptosis in acute shigellosis is asso-
ciated with increased production of Fas/Fas ligand, perforin, caspase-1, and
caspase-3 but reduced production of Bcl-2 and interleukin-2. Infect. Im-
mun. 70:3199–3207.
102a.Renesto, P., N. Crapoulet, H. Ogata, B. La Scola, G. Vestris, J. M. Claverie,
and D. Raoult. 2003. Genome-based design of a cell-free culture medium
for Tropheryma whipplei. Lancet 362:447–449.
103. Rogler, G., M. Hausmann, D. Vogl, E. Aschenbrenner, T. Andus, W. Falk,
R. Andreesen, J. Scholmerich, and V. Gross. 1998. Isolation and phenotypic
characterization of colonic macrophages. Clin. Exp. Immunol. 112:205–215.
104. Rosenberger, C. M., R. L. Gallo, and B. B. Finlay. 2004. Interplay between
antibacterial effectors: a macrophage antimicrobial peptide impairs intra-
cellular Salmonella replication. Proc. Natl. Acad. Sci. USA 101:2422–2427.
105. Rugtveit, J., P. Brandtzaeg, T. Halstensen, O. Fausa, and H. Scott. 1994.
Increased macrophage subset in inflammatory bowel disease: apparent re-
cruitment from peripheral blood monocytes. Gut 35:669–674.
106. Rumsaeng, V., W. W. Cruikshank, B. Foster, C. Prussin, A. S. Kirshenbaum,
T. A. Davis, H. Kornfeld, D. M. Center, and D. D. Metcalfe. 1997. Human
mast cells produce the CD4 T lymphocyte chemoattractant factor, IL-16.
J. Immunol. 159:2904–2910.
107. Schneider, T., A. Stallmach, A. von Herbay, T. Marth, W. Strober, and M.
VOL. 13, 2006 MINIREVIEWS 177
Zeitz. 1998. Treatment of refractory Whipple disease with interferon-gamma.
Ann. Intern. Med. 129:875–877.
107a.Schoedon, G., D. Goldenberger, R. Forrer, A. Gunz, F. Dutly, M. Hochli, M.
Altwegg, and A. Schaffner. 1997. Deactivation of macrophages with inter-
leukin-4 is the key to the isolation of Tropheryma whippelii. J. Infect. Dis.
176:672–677.
108. Schutyser, E., S. Struyf, P. Proost, G. Opdenakker, G. Laureys, B. Verhasselt,
L. Peperstraete, I. Van de Putte, A. Saccani, P. Allavena, A. Mantovani, and J.
Van Damme. 2002. Identification of biologically active chemokine isoforms
from ascitic fluid and elevated levels of CCL18/pulmonary and activation-
regulated chemokine in ovarian carcinoma. J. Biol. Chem. 277:24584–24593.
109. Schwan, W. R., X. Z. Huang, L. Hu, and D. J. Kopecko. 2000. Differential
bacterial survival, replication, and apoptosis-inducing ability of Salmonella
serovars within human and murine macrophages. Infect. Immun. 68:1005–
1013.
110. Seegert, D., P. Rosenstiel, H. Pfahler, P. Pfefferkorn, S. Nikolaus, and S.
Schreiber. 2001. Increased expression of IL-16 in inflammatory bowel dis-
ease. Gut 48:326–332.
111. Silva, M. T., P. M. Macedo, and J. F. Moura Nunes. 1985. Ultrastructure of
bacilli and the bacillary origin of the macrophagic inclusions in Whipple’s
disease. J. Gen. Microbiol. 131:1001–1013.
112. Smith, P. D., E. N. Janoff, M. Mosteller-Barnum, M. Merger, J. M. Orenstein,
J. F. Kearney, and M. F. Graham. 1997. Isolation and purification of CD14-
negative mucosal macrophages from normal human small intestine. J. Im-
munol. Methods 202:1–11.
113. Smith, P. D., L. E. Smythies, M. Mosteller-Barnum, D. A. Sibley, M. W.
Russell, M. Merger, M. T. Sellers, J. M. Orenstein, T. Shimada, M. F.
Graham, and H. Kubagawa. 2001. Intestinal macrophages lack CD14 and
CD89 and consequently are down-regulated for LPS- and IgA-mediated
activities. J. Immunol. 167:2651–2656.
114. Smythies, L. E., M. Sellers, R. H. Clements, M. Mosteller-Barnum, G.
Meng, W. H. Benjamin, J. M. Orenstein, and P. D. Smith. 2005. Human
intestinal macrophages display profound inflammatory anergy despite avid
phagocytic and bacteriocidal activity. J. Clin. Investig. 115:66–75.
115. Spo¨ttl, T., M. Hausmann, M. Kreutz, A. Peuker, D. Vogl, J. Scholmerich,
W. Falk, R. Andreesen, T. Andus, H. Herfarth, and G. Rogler. 2001. Mono-
cyte differentiation in intestine-like macrophage phenotype induced by
epithelial cells. J. Leukoc. Biol. 70:241–251.
116. Stern, M., J. Savill, and C. Haslett. 1996. Human monocyte-derived mac-
rophage phagocytosis of senescent eosinophils undergoing apoptosis. Me-
diation by v3/CD36/thrombospondin recognition mechanism and lack of
phlogistic response. Am. J. Pathol. 149:911–921.
117. Stoll, T., G. Keusch, R. Jost, H. Burger, and O. Oelz. 1993. IgA nephrop-
athy and hypercalcemia in Whipple’s disease. Nephron 63:222–225.
118. Takahashi-Iwanaga, H., T. Iwanaga, and H. Isayama. 1999. Porosity of the
epithelial basement membrane as an indicator of macrophage-enterocyte
interaction in the intestinal mucosa. Arch. Histol. Cytol. 62:471–481.
119. Tani, K., W. J. Murphy, O. Chertov, R. Salcedo, C. Y. Koh, I. Utsunomiya,
S. Funakoshi, O. Asai, S. H. Herrmann, J. M. Wang, L. W. Kwak, and J. J.
Oppenheim. 2000. Defensins act as potent adjuvants that promote cellular
and humoral immune responses in mice to a lymphoma idiotype and carrier
antigens. Int. Immunol. 12:691–700.
120. Tollin, M., P. Bergman, T. Svenberg, H. Jornvall, G. H. Gudmundsson, and
B. Agerberth. 2003. Antimicrobial peptides in the first line defence of
human colon mucosa. Peptides 24:523–530.
121. Van Epps, D. E., D. A. Durant, and J. W. Potter. 1983. Migration of human
helper/inducer T cells in response to supernatants from Con A-stimulated
suppressor/cytotoxic T cells. J. Immunol. 131:697–700.
121a.Whipple G. H. 1907. A hitherto undescribed disease characterized anatom-
ically by deposits of fat and fatty acids in the intestinal and mesenteric
lymphatic tissues. Bull. Johns Hopkins Hosp. 18:382–391.
122. Yang, D., A. Biragyn, L. W. Kwak, and J. J. Oppenheim. 2002. Mammalian
defensins in immunity: more than just microbicidal. Trends Immunol. 23:
291–296.
123. Zhang, Y., D. M. Center, D. M. Wu, W. W. Cruikshank, J. Yuan, D. W.
Andrews, and H. Kornfeld. 1998. Processing and activation of pro-interleu-
kin-16 by caspase-3. J. Biol. Chem. 273:1144–1149.
124. Zinkernagel, A. S., R. Gmur, L. Fenner, A. Schaffner, G. Schoedon, and M.
Schneemann. 2003. Marginal and subgingival plaque-a natural habitat of
Tropheryma whipplei? Infection 31:86–91.
125. Zychlinsky, A., C. Fitting, J. M. Cavaillon, and P. J. Sansonetti. 1994.
Interleukin 1 is released by murine macrophages during apoptosis induced
by Shigella flexneri. J. Clin. Investig. 94:1328–1332.
126. Zychlinsky, A., B. Kenny, R. Menard, M. C. Prevost, I. B. Holland, and P. J.
Sansonetti. 1994. IpaB mediates macrophage apoptosis induced by Shigella
flexneri. Mol. Microbiol. 11:619–627.
127. Zychlinsky, A., M. C. Prevost, and P. J. Sansonetti. 1992. Shigella flexneri
induces apoptosis in infected macrophages. Nature 358:167–169.
178 MINIREVIEWS CLIN. VACCINE IMMUNOL.
